Be Ready for Questions About Molnupiravir to Treat COVID-19

You'll hear buzz about molnupiravir, an oral antiviral to treat that it's under FDA review.

Molnupiravir blocks viral replication by incorporating itself into the RNA of SARS-CoV-2...causing viral death.

It's 4 capsules bid for 5 days...and seems well tolerated.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote